Study Details

Back to Search Results

A study in patients with metastatic prostate cancer to assess how the drug Eligard®, affects certain markers in blood and urine, which are indicators for the disease

Terminated/Withdrawn
The study has stopped early and will not start again. Participants were not enrolled (for withdrawn studies), however if participants were enrolled, they are no longer being examined or treated.

Clinicaltrials.gov ID

The unique identification code given to each clinical study upon registration at ClinicalTrials.gov.
NCT01933022

Astellas Study ID

The unique identification code given by the study sponsor.

EGD-EC-005

EudraCT ID

The unique identification code given to each clinical study upon registration at EudraCT (European Union Drug Regulating Authorities Clinical Trials Database).

2012-000101-69

Follow Trial

Condition

Prostate Cancer

Phase

These clinical trials happen after a drug or treatment has been approved for patients to take. Clinical trials in phase 4 usually take place over many years because researchers want to learn about long term use and safety of a drug or treatment.

Phase 4

Age

18 years - N/A

Sex

Male

Product

N/A

Type

A type of clinical study in which participants are assigned to groups that receive one or more intervention/treatment (or no intervention) so that researchers can evaluate the effects of the interventions on biomedical or health-related outcomes.

Interventional

Trial Dates

Aug 2014 - Aug 2015

Masking

None (Open Label)

Enrollment number

1

An exploratory, open label, single-arm study to evaluate the effect of Eligard® 6-month on biomarkers of disease in patients with metastatic prostate cancer

Study summary

Study documents

Study Documents, including study results, are available after a study is completed or terminated, according to Astellas Transparency policy.

Get More Information

Would you like more information about clinical trial sites that are recruiting participants for A study in patients with metastatic prostate cancer to assess how the drug Eligard®, affects certain markers in blood and urine, which are indicators for the disease? Contact us by filling our your information to the right and we’ll respond to you.

By clicking ["Continue/Submit"], you agree that Astellas may contact you by email with information to help you connect with clinical trial sites. While we can connect you to clinical trial sites, we cannot answer questions about any investigational therapy through email. Your consent to receiving emails is not a requirement to participate in a clinical trial or study. For more information, including how to unsubscribe at any time, see our Privacy Notice & Cookies Policy.

Locations

Site NL31005 St. Antonius ziekenhuis

Nieuwegein, Netherlands, 3435 CM

Site NL31001 Canisius-Wilhelmina Ziekenhuis

Nijmegen, Netherlands, 6532 SZ

Site NL31002 Ziekenhuisgroep Twente

Hengelo, Netherlands, 7555 DL

Site NL31004 Radboudumc

Nijmegen, Netherlands, 6525 GA

Site NL31003 Jeroen Bosch Ziekenhuis

's-Hertogenbosch, Netherlands, 5223 GZ

The purpose of this website is to offer education and information to patients and their families and friends, the public, and healthcare professionals about the clinical trial process. In addition, the website will provide specific information about Astellas clinical trials. Please read the complete Astellas Transparency Policy to learn about the clinical trial information available on this website

© ASTELLAS PHARMA GLOBAL DEVELOPMENT, INC.

POWERED BY:

Pharma Intelligence logo